PL2503338T3 - CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii - Google Patents

CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii

Info

Publication number
PL2503338T3
PL2503338T3 PL12002502T PL12002502T PL2503338T3 PL 2503338 T3 PL2503338 T3 PL 2503338T3 PL 12002502 T PL12002502 T PL 12002502T PL 12002502 T PL12002502 T PL 12002502T PL 2503338 T3 PL2503338 T3 PL 2503338T3
Authority
PL
Poland
Prior art keywords
biomarker
evaluate
therapy
effectiveness
disease development
Prior art date
Application number
PL12002502T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PL2503338T3 publication Critical patent/PL2503338T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL12002502T 2007-10-24 2008-10-15 CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii PL2503338T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP12002502.8A EP2503338B1 (en) 2007-10-24 2008-10-15 CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP08842581A EP2201376B1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
PL2503338T3 true PL2503338T3 (pl) 2015-06-30

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08842581T PL2201376T3 (pl) 2007-10-24 2008-10-15 Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia
PL12002502T PL2503338T3 (pl) 2007-10-24 2008-10-15 CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08842581T PL2201376T3 (pl) 2007-10-24 2008-10-15 Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia

Country Status (14)

Country Link
US (1) US20100209942A1 (pl)
EP (2) EP2201376B1 (pl)
JP (2) JP4982610B2 (pl)
KR (2) KR20160029869A (pl)
CA (1) CA2702635A1 (pl)
CY (2) CY1113403T1 (pl)
DK (2) DK2201376T3 (pl)
ES (2) ES2532361T3 (pl)
FI (1) FI20070795A0 (pl)
HR (2) HRP20120743T1 (pl)
PL (2) PL2201376T3 (pl)
PT (2) PT2201376E (pl)
SI (2) SI2201376T1 (pl)
WO (1) WO2009053523A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA2806301A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
PL2956772T3 (pl) * 2013-02-14 2018-12-31 Faron Pharmaceuticals Oy Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
GB201715115D0 (en) 2017-09-19 2017-11-01 Univ London Queen Mary Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007236A1 (en) * 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
WO1997013875A1 (en) 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7534423B2 (en) * 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
KR20100059902A (ko) 2010-06-04
JP2012159514A (ja) 2012-08-23
CY1113403T1 (el) 2016-06-22
ES2389751T3 (es) 2012-10-31
PL2201376T3 (pl) 2013-01-31
EP2201376A1 (en) 2010-06-30
DK2503338T3 (en) 2015-03-09
PT2503338E (pt) 2015-03-05
JP4982610B2 (ja) 2012-07-25
EP2503338A3 (en) 2013-03-13
EP2201376B1 (en) 2012-08-08
PT2201376E (pt) 2012-08-20
CY1116089T1 (el) 2017-02-08
JP2011501176A (ja) 2011-01-06
SI2503338T1 (sl) 2015-06-30
EP2503338B1 (en) 2014-12-24
KR20160029869A (ko) 2016-03-15
US20100209942A1 (en) 2010-08-19
HRP20150181T1 (hr) 2015-06-19
ES2532361T3 (es) 2015-03-26
EP2503338A2 (en) 2012-09-26
HRP20120743T1 (hr) 2012-10-31
SI2201376T1 (sl) 2012-09-28
EP2201376A4 (en) 2011-03-23
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
JP5619810B2 (ja) 2014-11-05
WO2009053523A1 (en) 2009-04-30
CA2702635A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
HRP20150181T1 (hr) Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
EP2649517A4 (en) Fast computer startup
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINES
BRPI0916931A2 (pt) agentes terapêuticos
DK2144905T3 (da) Terapeutiske midler
DK2035369T3 (da) Terapeutiske
EP2012795A4 (en) THERAPEUTIC TRITERPENOIDS
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
EP2367606A4 (en) BONDING BEHAVIOR SHOWING TOY
EP2074770A4 (en) LINK AGGREGATION
EP2110789A4 (en) PAPER MONEY PROCESSOR
BRPI0920850A2 (pt) novos compostos e sua utilização
IL192319A (en) Assessment of medical conditions
IL200091A0 (en) Use of chitosans for the treatment of nail inflammatory diseases
SMT201600041B (it) Agenti terapeutici 713
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
EP2222689A4 (en) COMPOUNDS FOR THERAPY AND DIAGNOSIS
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE